Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 10

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 10
---
 infertility rate in China was around 17.6% in 2020, representing an annual growth of 0.6%. Infertility is increasingly
gaining society’s attention as individuals are more openly discussing their struggles. Despite the prevalence of infertility, access
to treatment is often limited in the Asia Pacific region. According to CIC, financial challenges, costs of treatment, and limited availability
or capacity of fertility medical care are some of the main challenges in the fertility marketplace in Asia-Pacific region. Religious,
social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have children. We believe that we can help
address some of these key challenges of Asia-Pacific fertility industry.

History and Development of the Company

Prior to the Business Combination,
on April 29, 2021, A SPAC I Acquisition Corp. (“ASCA”), was incorporated as a British Virgin Islands business company,
specifically a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.

The Business Combination

On February 15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the “Merger Agreement,” and the
transactions contemplated thereunder, the “Business Combination”) with A SPAC I Mini Acquisition Corp., Merger Sub, NewGenIvf
Limited, a Cayman Islands exempted company (“Legacy NewGenIvf”) and certain shareholders of Legacy NewGenIvf. Pursuant to
the Merger Agreement, the Business Combination was effected in two steps: (i) ASCA was reincorporated to the British Virgin Islands
by merging with and into A SPAC I Mini Acquisition Corp. (such transaction, the “Reincorporation Merger”); and (ii) Merger
Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the Company (such second step
in isolation, the “Acquisition Merger”). The surviving entity of the Business Combination, together with its subsidiaries
is referred to in this prospectus as “NewGenIvf,” the “Company,” “we,” “our,” or “us,”
unless the context otherwise requires.

<div align='center'>1</div>

On June 12, 2023, the parties to the Merger Agreement entered into